COP化學治療療程
**COP療程**（環磷醯胺、長春新鹼、類固醇）是獸醫腫瘤學中常用的聯合細胞毒性療法，主要用於治療淋巴瘤。 > **臨床警告：** 長春新鹼是一種強烈的發泡劑。藥物外滲會導致嚴重的組織壞死。 **臨床提示：** 雖然多數腫瘤科醫師偏好CHOP療程，但高劑量COP療程在非專科環境中是一種非常實用且相對直接的有效方案。
作用機制: The COP protocol utilizes three distinct mechanisms to target neoplastic cells: * **Cyclophosphamide**: An alkylating agent that cross-links DNA strands → prevents DNA replication and transcription → induces cell death. * **Vincristine**: Binds to **tubulin** → inhibits microtubule formation and mitotic spindle assembly → arrests cell division in metaphase. * **Prednisolone**: A glucocorticoid that binds to specific intracellular receptors → alters gene expression → induces apoptosis in neoplastic lymphocytes.
各物種劑量
- COP Protocol - Induction (Cyclophosphamide) · 250 mg/m2 · PO · q21d · First 6 months · Administer with Furosemide to prevent haemorrhagic cystitis.
- COP Protocol - Induction (Vincristine) · 0.70 mg/m2 · IV · q7d for 4 weeks, then q21d · First 6 months · On q21d schedule, give on the same day as cyclophosphamide.
- COP Protocol - Induction (Prednisolone) · 2 mg/kg (week 1), 1.5 mg/kg (week 2), 1 mg/kg (week 3), 1 mg/kg thereafter · PO · q24h (weeks 1-3), then q48h · First 6 months · Tapering dose schedule.
- COP Protocol - Adjunct (Furosemide) · 1 mg/kg · PO · q12h · For 48h (4 doses) concurrent with cyclophosphamide · Administered to promote diuresis and reduce risk of haemorrhagic cystitis.
- COP Protocol - Maintenance after 6 months (Cyclophosphamide) · 250 mg/m2 · PO · q28d · Months 6 to 12 · Stop protocol after 12 months and monitor for relapse.
- COP Protocol - Maintenance after 6 months (Vincristine) · 0.70 mg/m2 · IV · q28d · Months 6 to 12 · Administer with cyclophosphamide.
- COP Protocol - Maintenance after 6 months (Prednisolone) · 1 mg/kg · PO · q48h · Months 6 to 12 · Stop protocol after 12 months and monitor for relapse.
- Alternative to Cyclophosphamide (Chlorambucil) · 20 mg/m2 · PO · As directed replacing cyclophosphamide · Ongoing · Use if haemorrhagic cystitis develops or if blood is noted on urine dipstick and culture is negative.
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
給藥途徑
禁忌症
- Severe neutropenia (< 2 x 10^9/L)
- Pre-existing haemorrhagic cystitis
- Known MDR1 mutation (requires extreme caution/dose adjustment for vincristine)
不良反應
- Myelosuppression (neutropenia)
- Haemorrhagic cystitis (cyclophosphamide)
- Gastrointestinal toxicity (vomiting, diarrhoea, anorexia)
- Tissue necrosis if extravasated (vincristine)
藥物相互作用
- Cimetidine · Inhibits hepatic cytochrome P450 enzyme pathway, potentially altering the metabolism and increasing toxicity of chemotherapeutics. · major
監測
- Haematology (prior to each vincristine treatment)
- Biochemistry (prior to first treatment, then minimum every 6 months)
- Free-catch urine dipstick (prior to each cyclophosphamide administration to check for blood)
- Urine culture (if blood is noted on dipstick)
過量
**Severe toxicity:** Overdose of these chemotherapeutics can lead to fatal myelosuppression, severe gastrointestinal sloughing, sepsis, and death. Extravasation of vincristine causes severe, progressive tissue necrosis requiring immediate management (e.g., hyaluronidase, warm compresses).
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。